CN110123874A - A kind of pharmaceutical composition for treating ischemia apoplexy sequelae - Google Patents
A kind of pharmaceutical composition for treating ischemia apoplexy sequelae Download PDFInfo
- Publication number
- CN110123874A CN110123874A CN201910374804.0A CN201910374804A CN110123874A CN 110123874 A CN110123874 A CN 110123874A CN 201910374804 A CN201910374804 A CN 201910374804A CN 110123874 A CN110123874 A CN 110123874A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- ischemia apoplexy
- treating ischemia
- apoplexy sequelae
- breviscapinun
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Plant Substances (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Neurology (AREA)
Abstract
The invention discloses a kind of pharmaceutical compositions for treating ischemia apoplexy sequelae, belong to drug field, pharmaceutical composition disclosed by the invention, more particularly to a kind of pharmaceutical composition combined with industrial hemp floral leaf extract and Breviscapinun, pharmaceutical composition disclosed by the invention had both clearly enhanced the effect of activating microcirculation and removing stasis medicinal dredging collateral, the repair to brain tissue impairment after being ill is enhanced again, is mainly used for the treatment of ischemia apoplexy sequelae.The pharmaceutical composition safe-dosaging limits are big, good effect, are a kind of pharmaceutical compositions with good development prospect.The medicinal application for being embodied as industrial hemp of the drug technique provides new developing direction, has good Social benefit and economic benefit.
Description
Technical field
The invention belongs to drug fields, and in particular to a kind of pharmaceutical composition for treating ischemia apoplexy sequelae.
Background technique
Apoplexy is the elderly's common disease, and in recent years, worldwide Apoplexy Morbidity has significant raising trend.Apoplexy
Later period often leaves many sequelae, such as hemiplegia, dementia, aphasia, causes greatly to patient, family and society
Pain and burden.And wherein ishemic stroke accounts for 80% or more, therefore, develops the medicine of effectively preventing ischemic apoplexy sequela
Object has good market prospects and social benefit.
And the reason of causing ishemic stroke series sequelae it is main there are two: 1, portion of tissue has thrombosis, causes
Entire brain blood supply is unsmooth；2, prolonged thrombus causes portion of tissue to be damaged, and it is not normal to cause partial function.
Modern medicine clinical research shows: Breviscapinun have expansion blood vessel, improve microcirculation, inhibit platelet aggregation,
The effects of anti-bolt thrombolysis.
2015, a kind of intravenous injection was made using cannabidiol exploitation in GW drugmaker, the U.S., which has obtained
Orphan drug qualification (also referred to as Orphan drug qualification, the Orphan Drug that U.S. Food and Drug Administration (FDA) authorizes
Designation), for treating hypoxic ischemic encephalopathy of newborn (NHIE).
A comment being published in for 2017 on " pharmacology forward position " (Frontiers in Pharmacology) is retouched
State how cannabidiol protects hippocampus under stress --- hippocampus is that responsible study, memory and navigation etc. are multinomial in brain
The part of critical function --- and potentially contribute to the destruction of brain cell caused by preventing schizophrenia.
Sufficiently think deeply and utilize industrial hemp floral leaf extract and the existing research achievement of Breviscapinun, the present invention provides
A kind of pharmaceutical composition for treating ischemia apoplexy sequelae, thrombolysis and blood circulation after apoplexy can either be promoted, and energy
The brain tissue damaged is repaired, the slight illness of paralytic is greatly alleviated, there is good social benefit and market value.
Summary of the invention
The purpose of the present invention is to provide a kind of pharmaceutical compositions for treating ischemia apoplexy sequelae.
The object of the present invention is achieved like this, a kind of pharmaceutical composition for treating ischemia apoplexy sequelae, special
Sign is: it is the pharmaceutically acceptable auxiliary material of industrial hemp floral leaf extract and Breviscapinun and the two by effective dose
The preparation being prepared.
Wherein the content of cannabidiol is 50% or more in the industrial hemp floral leaf extract.
Wherein the content of lamp-dish flower acetic is 50% or more in the Breviscapinun.
Wherein the mass ratio of the industrial hemp floral leaf extract and Breviscapinun is (1-5): 1.
Wherein the preparation formulation includes injection, tablet, granule, oral agents, dripping pill.
Wherein the injection is one of small needle, powder needle, glucose infusion liquid, sodium chloride infusion, pharmaceutic adjuvant used
Including diluent, osmotic pressure regulator, wherein the effective component industrial hemp floral leaf extract contained is 30-150mg/ bottles and lamp
10-60mg/ bottles of florigen of small cup.
The pharmaceutical composition for the treatment of ischemia apoplexy sequelae provided by the invention has given full play to two kinds of effective components
Advantage, facilitate push industrial hemp industry further development, have good Social benefit and economic benefit.
Specific embodiment
The present invention is further illustrated below, but the present invention is limited in any way, based on the present invention
It is made it is any transform or replace, all belong to the scope of protection of the present invention.
Embodiment 1
The present embodiment provides a kind of injections for treating ischemia apoplexy sequelae, operate as follows: weighing industrial hemp floral leaf
Extract 500mg, Breviscapinun 150mg, add water for injection 200mL, adjust pH value with 8% NaOH solution and make it dissolve；It is added
Sodium chloride 3g adds 0.2% active carbon to boil 15 minutes, and filtering, filtrate injects water to 1000mL；Medical fluid is with 0.22 μm
Miillpore filter filtration, rolls lid by filling 5 bottles, in 110 DEG C of pressure sterilizings 40 minutes to get.
Embodiment 2
The tablet that the present embodiment provides a kind of suitable for treating ischemia apoplexy sequelae operates as follows: weighing industrial hemp
Floral leaf extract 100g, Breviscapinun 30g, starch 355g, magnesium stearate 15g are mixed, and are pelletized, dry, tabletting, every slice weight
0.5g is to get Tabules of the invention.
Embodiment 3
The dripping pill that the present embodiment provides a kind of suitable for treating ischemia apoplexy sequelae operates as follows: weighing industrial hemp
Floral leaf extract 50g, Breviscapinun 10g, another taking polyethylene glycol 4000 and appropriate Macrogol 6000, are placed in 80-85 DEG C of water-bath
After middle heating melting, weighed above two raw material is added, mixes, is kept for 75 DEG C of temperature, instills in atoleine (0-5 DEG C),
1000 are made to get drops of the invention.
Claims (6)
1. a kind of pharmaceutical composition for treating ischemia apoplexy sequelae, it is characterised in that: it is the industry by effective dose
The preparation that cannabis leaf extract and Breviscapinun and the pharmaceutically acceptable auxiliary material of the two are prepared.
2. a kind of pharmaceutical composition for treating ischemia apoplexy sequelae according to claim 1, it is characterised in that: institute
The content for stating cannabidiol in industrial hemp floral leaf extract is 50% or more.
3. a kind of pharmaceutical composition for treating ischemia apoplexy sequelae according to claim 1, it is characterised in that: institute
The content for stating lamp-dish flower acetic in Breviscapinun is 50% or more.
4. a kind of pharmaceutical composition for treating ischemia apoplexy sequelae according to claim 1, it is characterised in that: institute
The mass ratio for stating industrial hemp floral leaf extract and Breviscapinun is (1-5): 1.
5. a kind of pharmaceutical composition for treating ischemia apoplexy sequelae according to claim 1, it is characterised in that: institute
Stating preparation formulation includes injection, tablet, granule, oral agents, dripping pill.
6. a kind of pharmaceutical composition for treating ischemia apoplexy sequelae according to claim 5, it is characterised in that: institute
Stating injection is one of small needle, powder needle, glucose infusion liquid, sodium chloride infusion, and pharmaceutic adjuvant used includes diluent, infiltration
Regulator is pressed, wherein the effective component industrial hemp floral leaf extract contained is 30-150mg/ bottles and Breviscapinun 10-60mg/
Bottle.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910374804.0A CN110123874A (en) | 2019-05-07 | 2019-05-07 | A kind of pharmaceutical composition for treating ischemia apoplexy sequelae |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910374804.0A CN110123874A (en) | 2019-05-07 | 2019-05-07 | A kind of pharmaceutical composition for treating ischemia apoplexy sequelae |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110123874A true CN110123874A (en) | 2019-08-16 |
Family
ID=67576548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910374804.0A Withdrawn CN110123874A (en) | 2019-05-07 | 2019-05-07 | A kind of pharmaceutical composition for treating ischemia apoplexy sequelae |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110123874A (en) |
-
2019
- 2019-05-07 CN CN201910374804.0A patent/CN110123874A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110123874A (en) | A kind of pharmaceutical composition for treating ischemia apoplexy sequelae | |
| CN102240393A (en) | Injection preparation containing argatroban | |
| CN101467967A (en) | Double-element solution type preparation for intravenous injection and intracerebral injection | |
| CN110063986A (en) | A kind of pharmaceutical composition of the leaf extract containing cannabis and preparation method thereof | |
| CN110101802A (en) | A kind of pharmaceutical composition for treating hypertension | |
| CN102961397B (en) | Pharmaceutical composition of fat emulsion injection and compound amino acid injection | |
| CN100584327C (en) | Medication composition in use for treating liver disease | |
| CN102258507A (en) | Ibuprofen-containing pharmaceutical composition and its preparation method and application | |
| CN102018665B (en) | Strictosamide injection and preparation method thereof | |
| CN1969927A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN101269115B (en) | Cardiac and cerebral vascular disease treating medicament preparation and method for preparing the same | |
| CN1969897A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1431002A (en) | Health care combination of propolis for reducing blood sugar and fat as well as method for mfg. its capsule | |
| CN100418513C (en) | Standby agent for treating burns | |
| CN103385883B (en) | Pharmaceutical composition containing tropisetron hydrochloride and fructose | |
| CN103239444A (en) | Dextroindobufen and clopidogrel compound drug composition | |
| CN1969939A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN102631421A (en) | Traditional Chinese medicine for treating senile dementia | |
| CN115554345B (en) | A Chinese medicinal compound preparation for treating gout and hyperuricemia, and its preparation method | |
| CN101721361A (en) | Pervone vincamine injection and preparation process thereof | |
| CN1969917A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969916A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969938A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969977A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof | |
| CN1969899A (en) | Pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, preparation process and quality control method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: No. 300, Southwest Forestry University, Panlong District, Kunming, Yunnan 650224 Applicant after: Luan Yunpeng Address before: 650000 No. 141 Chunyu Road, Wuhua District, Kunming City, Yunnan Province Applicant before: Luan Yunpeng |
|
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20190816 |